The phase 3 study findings of the single-drug head-to-head clinical trial between Ivonescimab, the world's first approved bispecific antibody independently developed by Zhongshan-based company Akeso, and Pembrolizumab were published in The Lancet, one of the world's top medical journals.

The single-drug head-to-head trial directly compares the efficacy of two drugs under the same conditions through clinical trials. The study finding shows that, compared to Pembrolizumab, Ivonescimab significantly prolonged patients' progression-free survival and reduced the risk of disease progression or death by 49%. Ivonescimab is also the world's first drug to outperform Pembrolizumab in a phase 3 single-drug head-to-head trial.

Ivonescimab (trade name: 依达方®) was approved for market by China's National Medical Products Administration in May 2024 for the treatment of non-small cell lung cancer.

As a globally competitive biopharmaceutical company that has grown and has been rooted in Zhongshan's Torch Development Zone for over a decade, Akeso always focuses on the development of innovative antibody drugs.